ストックスクリーナーアプリを入手
351.02
1.29%
-4.58
アフターアワーズ：
352.00
0.98
+0.28%
Amgen Inc (AMGN) 最新ニュース
Kelsey Financial LLC Makes New $7.13 Million Investment in Amgen Inc. $AMGN - MarketBeat
Sumitomo Mitsui Trust Group Inc. Has $527.74 Million Stock Position in Amgen Inc. $AMGN - MarketBeat
Robeco Institutional Asset Management B.V. Increases Stake in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Sold by KG&L Capital Management LLC - MarketBeat
Curtis Advisory Group Adds Amgen Shares to Portfolio - National Today
Factory Mutual Insurance Trims Amgen Stake - National Today
Amgen Inc. (AMGN): Billionaire Ken Fisher doubles bullish position - MSN
Clarity Wealth Advisors LLC Invests $3.91 Million in Amgen Inc. $AMGN - MarketBeat
Amgen (NASDAQ:AMGN) Upgraded by Wall Street Zen to Buy Rating - MarketBeat
Is It Time To Revisit Amgen (AMGN) After The Recent 4.6% Share Price Pullback - simplywall.st
Amgen Inc. stock underperforms Friday when compared to competitors - MarketWatch
China Approves Amgen's Tarlatamab for Previously Treated Extensive-Stage Small Cell Lung Cancer | PharmExec - Pharmaceutical Executive
Amgen’s FORWARD II Gout Study: What a Less Frequent Krystexxa Schedule Could Mean for Investors - TipRanks
Amgen-Backed DLL3 Combo Trial Could Be A Game Changer For Zai Lab (ZLAB) - simplywall.st
Why Amgen (AMGN) is Poised to Beat Earnings Estimates Again - Yahoo! Finance Canada
Amgen’s lung cancer drug tarlatamab wins China approval - WTAQ
Amgen (NASDAQ:AMGN) Price Target Raised to $326.00 - MarketBeat
Amgen’s Tarlatamab Approved in China - Pharmaceutical Executive
NK Cell Therapy Pipeline 2026: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Amgen, ImmunityBio, Dragonfly Therapeutics, Glycostem Therapeutics, Athenex, Artiva Biotherap - Barchart
Intratumoral Cancer Therapies Market: Expanding Revenue Landscape to 2034 – DelveInsight | Amgen, Daiichi Sankyo, AiViva BioPharma, Lytix Biopharma, Regeneron Pharma, Checkmate Pharma, Replimune - Barchart
OFI Invest Asset Management Increases Stake in Amgen - National Today
OFI Invest Asset Management Increases Stock Position in Amgen Inc. $AMGN - MarketBeat
Prime Capital Investment Advisors LLC Has $6.32 Million Stake in Amgen Inc. $AMGN - MarketBeat
Encompass Wealth Advisors Trims Amgen Stake by Over 50% - National Today
Atopic Dermatitis 68-Market Drug Forecast and Market Analysis Report 2023-2025 & 2025-2033 - GlobeNewswire Inc.
Amgen's lung cancer drug tarlatamab wins China approval - Reuters
Encompass Wealth Advisors LLC Sells 3,010 Shares of Amgen Inc. $AMGN - MarketBeat
Is Amgen (AMGN) One of the Most Profitable Value Stocks to Buy Right Now? - Yahoo Finance
Amgen (AMGN) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
What Amgen (AMGN)'s TEPEZZA On‑Body Injector Phase 3 Results Mean For Shareholders - simplywall.st
Lobbying Update: $50,000 of TIBER CREEK HEALTH STRATEGIES INC. ON BEHALF OF AMGEN INC. lobbying was just disclosed - Quiver Quantitative
Guggenheim Adjusts Amgen (AMGN) Price Target to $351, Maintains - GuruFocus
Investors heavily search Amgen Inc. (AMGN): Here is what you need to know - MSN
Eli Lilly Vs. Amgen: Who Leads Obesity And IMIDs (NASDAQ:AMGN) - Seeking Alpha
Guggenheim Maintains Amgen(AMGN.US) With Hold Rating, Raises Target Price to $351 - Moomoo
Guggenheim raises Amgen stock price target to $351 on product mix - Investing.com Canada
Amgen (AMGN) Stock: GLP-1 Drug MariTide Drives Analyst Optimism - CoinCentral
We Picked Amgen Stock a Year Ago. Stick With the Emerging GLP-1 Play. - Barron's
Cantor Fitzgerald Maintains Amgen(AMGN.US) With Hold Rating, Maintains Target Price $350 - Moomoo
Amgen (AMGN) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance
Amgen Inc. stock outperforms competitors on strong trading day - MarketWatch
Viridian Therapeutics: Why Elegrobart Phase 3 Results Fail To Challenge Amgen (NASDAQ:VRDN) - Seeking Alpha
Truist raises Amgen stock price target to $325 on revenue outlook - Investing.com
Amgen’s Tepezza On Body Injector Data Tests Thyroid Eye Disease Moat - simplywall.st
Is Amgen Stock Poised For A Rally? - Trefis
Cantor Fitzgerald maintains Amgen stock rating ahead of earnings - Investing.com
Amgen releases positive topline results from phase 3 trial of teprotumumab-trbw (TEPEZZA) - Ophthalmology Times
BIP Wealth LLC Boosts Amgen Stake by Over 800% - National Today
BIP Wealth LLC Acquires 8,785 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen’s TEPEZZA Injector Data Sparks Questions On Value And Competition - Yahoo Finance
Amgen Inc CEO Robert A. Bradway 2025 total compensation $24.7 million - marketscreener.com
Amgen's Thyroid Eye Disease Data Rocks Rival Viridian, Makes It The Better Buy (AMGN) - Seeking Alpha
Amgen Stock Price Expected to Rise, Analyst Says - National Today
Stifel sees path towards differentiation for Viridian after Amgen data - Yahoo Finance
Amgen Shares Sold by KFG Wealth Management - National Today
Investors Are Actively Looking Into Amgen Inc. (AMGN): Key Information You Should Be Aware Of - Bitget
Amgen (NASDAQ:AMGN) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says - MarketBeat
Here's Why Amgen (AMGN) is a Strong Value Stock - Yahoo Finance
AMGN's Subcutaneous Tepezza Scores Phase III Win in Thyroid Eye Disease - Yahoo Finance Singapore
Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know - Yahoo Finance
ONTARIO AND QUEBEC EXPAND PUBLIC COVERAGE OF REPATHA® FOR ELIGIBLE RECENT ACUTE CORONARY SYNDROME PATIENTS - Newswire Canada
Oncolytic Virus Therapies Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | CG Oncology, Imugene, Amgen, Daiichi Sankyo, Genelux, Replimune, Binhui Biopharma - Barchart
Robinhood Asset Management LLC Makes New Investment in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Sold by KFG Wealth Management LLC - MarketBeat
Amgen reports positive Phase III findings for subcutaneous Tepezza trial - Yahoo
Citi Maintains Amgen(AMGN.US) With Hold Rating, Maintains Target Price $345 - Moomoo
2.18%
0.21%
大文字化:
|
ボリューム (24 時間):